JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

B5953 Dovitinib (TKI258) Lactate

Target: CSF-1R|FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Oral tyrosine kinase inhibitor (TKI) against FGFR1–3, VEGFR1–3, and platelet-derived growth factor receptor (PDGFR).

insoluble in EtOH; ≥10.62 mg/mL
C3342 MAZ51

Target: VEGFR

Summary: VEGFR3 antagonist

insoluble in EtOH; insoluble in H2O; ≥31.4 mg/mL
A3009 Sorafenib
2 Citation

Target: Raf|VEGFR

Summary: Raf kinases and tyrosine kinases inhibitor

≥23.25 mg/mL
A3022 Pazopanib (GW-786034)

Target: CSF-1R|VEGFR|PDGFR|c-Kit|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in EtOH; insoluble in H2O; ≥10.95 mg/mL
A3750 Regorafenib hydrochloride

Target: Raf|VEGFR|PDGFR|c-Kit|c-RET

Summary: Tyrosine kinase inhibitor

≥25.95 mg/mL
A3843 SU 5402

Target: VEGFR|PDGFR|FGFR

Summary: VEGFR2/FGFR/PDGFR/EGFR inhibitor

insoluble in EtOH; insoluble in H2O; ≥14.8 mg/mL
A3847 SU5416

Target: VEGFR

Summary: VEGF receptor inhibitor and AHR agonist

insoluble in EtOH; insoluble in H2O; ≥11.9 mg/mL